For all media enquiries, please contact Breakthrough Media Centre:
Press office
Email: press@breakthrough.org.uk
Tel: 020 7025 2432 / 2460
Fax: 020 7025 2401
Out of hours: 07778 682001
News and Events
-
HRH The Prince of Wales officially opens the Edinburgh Research Unit
05 Jun 2008Breakthrough Breast Cancer’s groundbreaking new research unit in Edinburgh is officially opened today by HRH The Prince of Wales (also known as The Duke of Rothesay while travelling in Scotland), the charity’s Patron.
-
Professor Alan Ashworth, Director of the Breakthrough Breast Cancer Research Centre, becomes a Fellow of the Royal Society
16 May 2008Professor Alan Ashworth, Director of the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research in London, has today been elected as a Fellow of the Royal Society.
-
CDK10 is an Important Determinant of Resistance to EndocrineTherapy
05 Feb 2008Scientists at the Breakthrough Breast Cancer Research Centre have identified how some breast cancers may become resistant to hormone treatments like tamoxifen. The study, published in the February issue of Cancer Cell, shows for the first time that a protein called CDK10 is able to control the development of tamoxifen resistance in hormone sensitive breast cancer, and has potentially important implications in the treatment of women with this form of the disease.
-
Debate at NCRI conference
25 Sep 2007Breakthrough Breast Cancer and Breast Cancer Campaign will be holding a joint debate at the NCRI conference in Birmingham on Sunday 30th September. The debate is titled 'Breast cancer prevention in 2025: targeted chemoprevention or lifestyle change'.
-
Patients begin enrolling in studies to determine if women with BRCA 1 & 2 positive cancer may receive greater benefit from new treatment
19 Jun 2007AstraZeneca Collaborates with Myriad Genetics on Phase 2 Trials. AstraZeneca (NYSE: AZN) today announced the start of two Phase II trials for a new compound being tested to treat patients with BRCA 1 & 2 positive breast and ovarian cancer. Myriad Genetics, Inc. (Nasdaq: MYGN, www.myriad.com), is providing the molecular diagnostic testing (BRACAnalysis™) for these trials. Dr Andrew Tutt, clinician scientist at the Breakthrough Breast Cancer Research Centre and breast oncologist at Guy’s Hospital, London is Lead Investigator for the trials.
-
BRCA1 dysfunction in sporadic basal-like breast cancer
29 Mar 2007Breakthrough scientists have identified a high prevalence of BRCA1 dysfunction in basal-like breast cancers. This finding could be exploited to develop novel targeted therapies for this particular type of breast cancer.
-
FGFR1 as a potential therapeutic target for lobular breast carcinomas
11 Dec 2006Breakthrough scientists have identified FGFR1 as a potential therapeutic target, for lobular breast carcinomas. The findings now published in the Journal of Clinical Cancer Research.
-
Are biomarker changes preferable to clinical response as markers of treatment benefit? An evening debate.
28 Sep 2006Professor Mitch Dowsett will be speaking at this years joint debate, hosted by Breakthrough Breast Cancer and Breast Cancer Campaign, at the NCRI conference.
